Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron in Women with IBS
NCT03806127Phase 2Completed
- Sponsor
- Urovant Sciences
- Start
- Dec 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Vibegron 75 mg with Placebo (2 arms). Primary endpoint: Number of IBS-D Participants Who Were Abdominal Pain Intensity (API) Weekly Responders at 12 weeks. Started Dec 2018; status: completed.
02
Drugs
vibegron
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT03806127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806127.